Empagliflozin vs Dapagliflozin in Heart Failure: a Target Trial Emulation

This publication has 34 references indexed in Scilit:

• Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure
  JAMA Network Open, 2024
• Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods
  ESC Heart Failure, 2023
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
  JACC, 2022
• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
  New England Journal of Medicine, 2020
• Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
  CPT: Pharmacometrics & Systems Pharmacology, 2020
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
  New England Journal of Medicine, 2019
• Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis
  Statistics in Medicine, 2016
• Active-comparator design and new-user design in observational studies
  Nature Reviews Rheumatology, 2015
• The Danish Civil Registration System as a tool in epidemiology
  European Journal of Epidemiology, 2014
• The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experiments
  Statistics in Medicine, 2013